INITIAL ASSESSMENT OF REAL-WORLD USAGE OF EXTENDED-RELEASE INJECTABLE PALIPERIDONE PALMITATE AMONG MEDICAID INSURED SCHIZOPHRENIA PATIENTS

被引：0
|
作者：
Kamat, S. [1 ]
Gutierrez, B. [1 ]
Eramo, A. [2 ]
Zubek, D. [1 ]
Baker, R. A. [3 ]
Lin, J. [4 ]
Karson, C. [5 ]
机构：
[1] Otsuka Amer Pharmaceut Inc, Princeton, NJ USA
[2] H Lundbeck & Co AS, Copenhagen, Denmark
[3] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA
[4] Novosys Hlth, Flemington, NJ USA
[5] CNK Consulting, Wayne, PA USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.1580
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A61 / A61
页数：1
相关论文
共 50 条
  • [41] COMPARISON OF SERUM PROLACTINE LEVELS BETWEEN RISPERIDONE AND PALIPERIDONE EXTENDED-RELEASE IN FEMALE PATIENTS WITH SCHIZOPHRENIA
    Albayrak, Y.
    Beyazyuz, M.
    Ozturk, N.
    Binbay, Z.
    Kuloglu, M.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [42] “Real world” clinical effectiveness of paliperidone palmitate 3-monthly injectable in early psychosis patients
    Vincent Ferraro
    Simon Lafrenière
    Marie-France Demers
    Marc-André Roy
    Amal Abdel-Baki
    Psychopharmacology, 2020, 237 : 3795 - 3797
  • [43] Safety of blonanserin (BNS) and paliperidone extended-release (PAL-ER) in patients with acute schizophrenia
    Sanada, K.
    Iwanami, A.
    Saito, K.
    Morita, T.
    Azuma, K.
    Yoshizawa, T.
    Tamura, T.
    Tsukurimichi, A.
    Kawamura, Y.
    Uchida, E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S469 - S470
  • [44] Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms
    Canuso, C. M.
    Bossie, C. A.
    Turkoz, I.
    Alphs, L.
    SCHIZOPHRENIA RESEARCH, 2009, 113 (01) : 56 - 64
  • [45] Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
    Turkoz, Ibrahim
    Wong, Joshua
    Chee, Benjamin
    Siddiqui, Uzma
    Knight, R. Karl
    Richarz, Ute
    Correll, Christoph U.
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2023, 13
  • [46] Real-world treatment patterns among attention-deficit/hyperactivity disorder patients who initiated extended-release treatment
    Erensen, Jennifer
    Wang, Xuezhe
    Ding, Yingjie
    Corvino, Frank A.
    Mikl, Jaromir
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 275 - 276
  • [47] Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
    Germain, Michael J.
    Paul, Subir K.
    Fadda, George
    Broumand, Varshasb
    Nguyen, Andy
    McGarvey, November H.
    Gitlin, Matthew D.
    Bishop, Charles W.
    Csomor, Philipp
    Strugnell, Stephen
    Ashfaq, Akhtar
    BMC NEPHROLOGY, 2022, 23 (01)
  • [48] Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
    Dickson, Matthew C.
    Nguyen, Michael M.
    Patel, Charmi
    Grabich, Shannon C.
    Benson, Carmela
    Cothran, Terry
    Skrepnek, Grant H.
    ADVANCES IN THERAPY, 2023, 40 (01) : 349 - 366
  • [49] SCHIZOPHRENIA MANAGEMENT: REAL-WORLD EXPERIENCE FROM NEW ZEALAND USING THREE-MONTHLY PALIPERIDONE PALMITATE
    Cassidy, C.
    Miles, W.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2021, 55 (1_SUPPL): : 84 - 84
  • [50] Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
    Matthew C. Dickson
    Michael M. Nguyen
    Charmi Patel
    Shannon C. Grabich
    Carmela Benson
    Terry Cothran
    Grant H. Skrepnek
    Advances in Therapy, 2023, 40 : 349 - 366
12345